Green Cross LabCell announced a joint research collaboration to develop low immunogenicity, high-performance natural killer (NK) anticancer treatment. The project, which is part of the Canada-South Korea Science, Technology and Innovation Projects sponsored by the National Research Council of Canada and the Korea Institute for Advancement of Technology (KIAT), aims at facilitating R&D collaboration between Canadian and South Korean innovators. Green Cross LabCell has developed the technology and expertise for the mass production of human NK cells by successfully conducting a first-in-human clinical trial using healthy donor-derived allogeneic NK cells and by developing CAR-NKs to enhance anti-tumor specificity and efficacy. The Feldan Shuttle technology is an innovative peptide-based delivery system that enables highly efficient transduction of foreign proteins into cells. Feldan Therapeutics can use its platform to deliver CRISPR nucleases and edit the genome of human NK cells. The collaboration combines both breakthrough technologies to develop next generations of specific and hyperactive off-the-shelf NK cells for allogeneic immuno-oncology therapies. Feldan Therapeutics and Green Cross LabCell started working together in 2016 to develop the basic research structure of this new NK-cell based immunotherapy project.